President Joe Biden’s revolutionary proposal to move marijuana to Schedule 3 of the Controlled Substances Act might mean the end of more than 50 years of “failed policy” as well as new opportunities in science and business.
But such a move wouldn’t change the federal government’s classification of psilocybin as more dangerous than the fentanyl fueling the country’s overdose crisis.
Psilocybin – the psychoactive ingredient in so-called magic mushrooms – is another increasingly popular drug with tremendous therapeutic potential and virtually no potential for fatal overdoses.
Rescheduling mushrooms
The Controlled Substances Act still classifies psilocybin mushrooms as a Schedule 1 drug – the same designation currently shared by marijuana.
And in the same paradox that’s bamboozled marijuana researchers and reform advocates, it is hard to conduct the necessary research proving psilocybin’s relative safety and therapeutic potential until restrictions are relaxed.
Could President Biden or the U.S. Congress turn to psilocybin rescheduling after the marijuana job is completed (whenever that might be)?
